
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
Novacea halts ASCENT-2 trial
Novacea halts ASCENT-2 trial
SOUTH SAN FRANCISCO, CaliforniaNovacea, Inc has ended its phase III ASCENT-2 clinical trial of Asentar (DN-101), the company's investigational cancer therapy for the treatment of androgen-independent prostate cancer. The trial was halted due to an imbalance of deaths between the two treatment arms, as observed by the study's Data Safety Monitoring Board. The study was comparing the benefits of weekly Asentar, an oral, intermittent high dose of calcitriol, plus docetaxel (Taxotere) with the current standard of care. The company plans to fully analyze the data to attempt to understand the cause of the higher death rate in the Asentar/Taxotere treatment group.
Articles in this issue
over 18 years ago
Third-line single-agent cetuximab ups overall survivalover 18 years ago
Modern multislice CT propels pancreas imaging forwardover 18 years ago
Sorafenib gets ok for liver cancerover 18 years ago
Celgene to acquire Pharmionover 18 years ago
RT/temozolomide raises possibility of cure in glioblastomaover 18 years ago
Brachytherapy as effective in younger as in older menover 18 years ago
MMA not harming patientsover 18 years ago
Kinase inhibitor may prevent RT-induced lung injuryover 18 years ago
FDA approves lower starting dose for dasatinib for CMLover 18 years ago
Encouraging Avastin results in glioblastoma multiformeNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.

























































